Kala Pharmaceuticals Inc. (NASDAQ:KALA) has announced its Q3 2020 financial results in which net product revenue was $2.2 million relate to INVELTYS sales and provided a business update.#
Kala receives approval from the FDA for EYSUVIS in dry eye disease
Mark Iwicki, the company’s CEO and President indicated that they had a strong third quarter, and the fourth quarter started strongly with EYSUVIS approval. Mark said that the company plans to launch EYSUVIS as the first prescription therapy for treating dry eye disease patient by the end of the year. The Kala novel AMPPLIFY tech-enabled EYSUVIS treatment can address the significant unmet need for patients and eye care professionals after an FDA-approved effective, fast-acting and safe, dry eye disease therapy. Iwicki confirmed that the company is currently in a sting position financially to commercialize EYSUVIS and INVELTYS to offer eye care professionals and patients access to the innovative therapies.
In October the FDA approved EYSUVIS as a short-term treatment for dry eys disease symptoms and signs. The FDA gave the EYSUVIS approval based on data from four clinical studies that enrolled around 2800 patients. The trials demonstrated significant and rapid improvement signs and symptoms of DED in the patients. The therapy demonstrated a favourable safety profile across the trials with adverse effects and increased in intraocular pressure comparable to the placebo.
Kala to leverage its ophthalmic team for the launch of EYSUVIS
The company plans to leverage the established and experienced ophthalmic team that fruitfully launched INVELTYS last year for the launch of EYSUVIS. Kala’s focus is on optometrists and ophthalmologists treating dry eye diseases patient and responsible for around 85% of total market prescription.
Uptake of INVELTYS® continues to be healthy, and in the third quarter, there were 38,000 INVELTYS prescriptions reported by Symphony Health. This represents 84% QoQ which is a sign of recovery of ocular surgeries following the relaxation of COVID-19 restriction on elective surgeries. With ocular surgeries being rescheduled, the company is optimistic that INVELTYS prescriptions will continue growing despite the impact of the pandemic.
